China Vanke Shares Jump as Beijing Moves to Ease Debt Pressure 
Mercedes-Benz Eyes €800 Million Labor Cost Cuts in Germany 
Anthropic’s Claude Discovers CRISPR-Like Enzyme System 
Gold Prices Rise as Oil Slide Eases Fed Rate Hike Fears 
Asian Stocks Fall as Bond Yields Surge Ahead of Trump-Xi Summit 
Paramount-Warner Bros $110 Billion Deal Draws Antitrust Backlash 
RBA Says ASX Still Falls Short on Governance and Risk Controls 
Gold Prices Rise as Oil Slump Eases Fed Rate Hike Fears 
European Stocks Slip as Iran Tensions Offset Strong Eurozone Data 
Asian Currencies Muted as Dollar Firms Ahead of Trump-Xi Summit 
U.S. 10-Year Treasury Yield Hits 2007 High as Fed Rate Hike Bets Rise 
McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
Microsoft Stock Upgraded as Stifel Sees Stronger Azure Growth 
Russian Envoy Dmitriev Heads to US for Ukraine Talks 
US Northeast Airports Resume Operations After Telecom Outage Disrupts Thousands of Flights 
South Korea, US Discuss Warship Building Cooperation 
fnny Beta Launches With a Simple Idea: Find an Event, Show Up, Get Rewarded 
Add as a preferred source on Google
Pharmacy benefit manager shares dropped sharply Wednesday as lawmakers introduced bipartisan legislation requiring health insurers and PBMs to divest pharmacy operations within three years. The proposal intensifies scrutiny of the PBM industry's influence over drug pricing.
Bipartisan Bill Targets Vertical Integration in Healthcare
According to Reuters, following the presentation of a bipartisan measure on Wednesday, which would compel health insurers or drug intermediaries to sell off their pharmacy businesses, shares of companies owning pharmacy benefit managers declined.
The majority of pharmacy benefit management (PBM) in the US is controlled by CVS Health’s Caremark, Cigna’s Express Scripts, and UnitedHealth Group’s Optum. All three of these parent firms also own health insurance businesses.
Following the initial reporting of the bill in the Wall Street Journal, all three firms' shares fell by 4.8% to 5.5%.
The bill, which is being co-sponsored by Republican Josh Hawley and Democratic Elizabeth Warren in the United States Senate, would require, within three years, that companies that own health insurers or pharmacy benefit managers sell their shares in pharmacies.
Healthcare Stocks React to Bipartisan Proposal
This bill will be submitted in Congress with the support of Republican Diana Harshbarger and Democratic Jake Auchincloss.
Pharmacy benefit managers (PBMs) mediate pricing negotiations for prescription prescriptions between insurance companies, pharmacies, and pharmaceutical companies. PBMs then pay pharmacies directly for the medications covered by their contracts.
They have already been investigated for the impact they have on the cost of prescription drugs.
"PBMs have manipulated the market to enrich themselves — hiking up drug costs, cheating employers, and driving small pharmacies out of business. My new bipartisan bill will untangle these conflicts of interest by reining in these middlemen," Senator Warren stated.
Other Insurers Feel the Ripple Effect of PBM Legislation
Other insurance companies' stock prices dropped 1% to 3%. This included Centene, Elevance, and Humana, Investing.com shares.
"The latest introduction of potential legislation to restrict PBM operations and broader healthcare vertical integration is unlikely to gain traction, although it is hard to dismiss outright," Michael Cherny, an analyst at Leerink Partners, said.
Insurance company stock has taken a beating following last week's shooting death of UnitedHealth health insurance unit CEO Brian Thompson outside a Manhattan hotel.
